Jiangsu Recbio Technology Co., Ltd. (2179.HK)
2179.HK Stock Price Chart
Explore Jiangsu Recbio Technology Co., Ltd. interactive price chart. Choose custom timeframes to analyze 2179.HK price movements and trends.
2179.HK Company Profile
Discover essential business fundamentals and corporate details for Jiangsu Recbio Technology Co., Ltd. (2179.HK) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
31 Mar 2022
Employees
531.00
Website
https://www.recbio.cnCEO
Yong Liu
Description
Jiangsu Recbio Technology Co., Ltd., a vaccine company, engages in the research, development, and commercialization of subunit vaccines in the People's Republic of China. The company is developing vaccines for the treatment of cervical cancer and genital warts, including REC603, a recombinant human papillomavirus (HPV) 9-valent vaccine that is in phase III clinical trial; REC601 and REC602 recombinant HPV bivalent vaccines, which are in phase I clinical trials; REC604a, a recombinant HPV quadrivalent vaccine that is in pre-clinical stage; and REC604b, a recombinant HPV 9-valent vaccine that is in pre-clinical stage. It is also developing ReCOV, a recombinant COVID-19 vaccine candidate that is in Phase II/III trial; and R520A, a messenger ribonucleic acid COVID-19 vaccine candidate that is in pre-clinical stage; REC610, a recombinant shingles vaccine that is in pre-clinical stage; REC607, a virus vectored adult tuberculosis vaccine that is in pre-clinical stage; REC606, a recombinant adult tuberculosis vaccine that is in pre-clinical stage; REC617, a recombinant influenza quadrivalent vaccine that is in pre-clinical stage; and REC605, a recombinant hand-foot-mouth disease quadrivalent vaccine that is in pre-clinical stage. The company was founded in 2011 and is based in Taizhou, the People's Republic of China.
2179.HK Financial Timeline
Browse a chronological timeline of Jiangsu Recbio Technology Co., Ltd. corporate events including earnings releases, dividend announcements, and stock splits.
Earnings released on 8 May 2025
Earnings released on 31 Dec 2024
EPS came in at -$0.35 , while revenue for the quarter reached $4.99M .
Earnings released on 30 Sept 2024
EPS came in at -$0.36 , while revenue for the quarter reached $5.19M .
Earnings released on 30 Jun 2024
EPS came in at -$0.28 , while revenue for the quarter reached $9.46M .
Earnings released on 8 May 2024
EPS came in at -$0.28 , while revenue for the quarter reached $9.53M .
Earnings released on 31 Dec 2023
EPS came in at -$0.35 , while revenue for the quarter reached $14.27M .
Earnings released on 30 Sept 2023
EPS came in at -$0.33 , while revenue for the quarter reached $13.83M .
Earnings released on 30 Jun 2023
EPS came in at -$0.31 , while revenue for the quarter reached $2.49M .
Earnings released on 31 Mar 2023
EPS came in at -$0.32 , while revenue for the quarter reached $2.62M .
Earnings released on 31 Dec 2022
EPS came in at -$0.44 , while revenue for the quarter reached $1.91M .
Earnings released on 30 Sept 2022
EPS came in at -$0.42 , while revenue for the quarter reached $1.84M .
Earnings released on 30 Jun 2022
EPS came in at -$0.44 , while revenue for the quarter reached $1.15M .
Earnings released on 31 Mar 2022
EPS came in at -$0.46 , while revenue for the quarter reached $1.21M .
Earnings released on 31 Dec 2021
EPS came in at -$0.37 , while revenue for the quarter reached $3.41M .
Earnings released on 30 Sept 2021
EPS came in at -$0.50 .
Earnings released on 30 Jun 2021
EPS came in at -$0.50 .
Earnings released on 31 Mar 2021
EPS came in at -$0.50 .
Earnings released on 31 Dec 2020
EPS came in at -$0.32 , while revenue for the quarter reached $1.57M .
2179.HK Stock Performance
Access detailed 2179.HK performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.